The "Inhaled Therapy" Revolution: How 2026 is Delivering Treatment Directly to the Lungs.
By mid-2026, the industry has officially entered the era of "Local-Action Delivery." This year, the focus is on the surge of Inhaled Dry-Powder Antifungals, which are achieving a 7.21% CAGR by delivering medication directly to the site of infection while avoiding systemic side effects like liver toxicity. This innovation is a primary driver for the market, as it allows for long-term...
0 التعليقات 0 المشاركات 30 مشاهدة 0 معاينة